TY - JOUR T1 - Covasim: an agent-based model of COVID-19 dynamics and interventions JF - medRxiv DO - 10.1101/2020.05.10.20097469 SP - 2020.05.10.20097469 AU - Cliff C. Kerr AU - Robyn M. Stuart AU - Dina Mistry AU - Romesh G. Abeysuriya AU - Gregory Hart AU - Katherine Rosenfeld AU - Prashanth Selvaraj AU - Rafael C. Núñez AU - Brittany Hagedorn AU - Lauren George AU - Amanda Izzo AU - Anna Palmer AU - Dominic Delport AU - Carrie Bennette AU - Bradley Wagner AU - Stewart Chang AU - Jamie A. Cohen AU - Jasmina Panovska-Griffiths AU - Michał Jastrzębski AU - Assaf P. Oron AU - Edward Wenger AU - Michael Famulare AU - Daniel J. Klein Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/05/15/2020.05.10.20097469.abstract N2 - The COVID-19 pandemic has created an urgent need for models that can project epidemic trends, explore intervention scenarios, and estimate resource needs. Here we describe the methodology of Covasim (COVID-19 Agent-based Simulator), an open-source model developed to help address these questions. Covasim includes demographic information on age structure and population size; realistic transmission networks in different social layers, including households, schools, workplaces, and communities; age-specific disease outcomes; and intrahost viral dynamics, including viral-load-based transmissibility. Covasim also supports an extensive set of interventions, including non-pharmaceutical interventions, such as physical distancing, hygiene measures, and protective equipment; and testing interventions, such as symptomatic and asymptomatic testing, isolation, contact tracing, and quarantine. These interventions can incorporate the effects of delays, loss-to-follow-up, micro-targeting, and other factors. In collaboration with local health agencies and policymakers, Covasim has already been applied to examine disease dynamics and policy options in Africa, Europe, Oceania, and North America.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Bill and Melinda Gates through the Global Good Fund.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data and source code are available; details are available in the manuscript. ER -